Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Relay Therapeutics, Inc. RLAY

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
129.02
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell 3 1 — 4 — 1 4 1 3 6 4 3
Insider Ownership
15.41%

Capital & Financial Ratios

Market Cap
4,210.00
Revenue
11.03
Net Income
(286.04)
Free Cash Flow
(212.20)
Net Debt
(910.93)
Current Ratio
18.27
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
346.61
P/B ratio
4.29
Past 5Y EPS Growth
(23.05%)
This Y EPS Growth
0.35%
Next Y EPS Growth
(0.73%)
Next 5Y EPS Growth
(0.23%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 750.09 781.32 554.52 910.93
Receivables — — — —
Inventory — — — —
Other 3.32 10.53 5.97 8.41
770.10 809.20 578.28 928.08
2023 2024 2025 Q'26
Payables 9.21 14.10 7.71 11.46
ST’ Debt — — — —
Other 1.20 1.99 0.46 1.25
30.27 50.73 25.58 50.80
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 3.00 0.35 — —
—
’25 7.68 0.68 — 7.00
15.36
’24 10.01 — — —
10.01
’23 0.23 0.12 25.20 0.00
25.55
’22 0.42 0.37 0.34 0.25
1.38
’21 0.95 0.84 0.67 0.57
3.03
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (51.11) (54.11) — —
—
’25 (73.21) (55.26) (62.12) (44.86)
(235.45)
’24 (50.32) (65.83) (75.08) (57.87)
(249.11)
’23 (67.13) (68.60) (75.40) (89.19)
(300.32)
’22 (49.17) (57.09) (66.14) (57.08)
(229.49)
’21 46.64 (28.14) (53.20) (39.71)
(74.41)
’20 (22.33) (20.84) (24.04) (35.27)
(102.49)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (51.11) (54.11) — —
—
’25 (73.59) (55.29) (62.12) (44.87)
(235.86)
’24 (52.10) (65.84) (75.31) (57.87)
(251.12)
’23 (69.04) (70.10) (75.99) (89.31)
(304.44)
’22 (51.97) (58.95) (68.24) (59.39)
(238.55)
’21 46.16 (28.52) (54.93) (40.59)
(77.88)
’20 (23.35) (21.26) (24.47) (35.34)
(104.42)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.41) (0.41) — —
—
’25 (0.46) (0.41) (0.43) (0.32)
(1.61)
’24 (0.62) (0.69) (0.63) (0.45)
(2.36)
’23 (0.78) (0.81) (0.54) (0.67)
(2.79)
’22 (0.57) (0.71) (0.76) (0.56)
(2.59)
’21 (0.47) (2.10) (0.66) (0.62)
(3.82)
’20 (0.28) (6.06) (2.38) 0.39
(2.56)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 12.65 5.95 4.01 1.78 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 35.36 23.18 12.14 9.04 — — —
High Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 327 323 261 192 — — —
Employees
— — — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.08 0.04 0.08 — — —
Revenue/Emp
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 1.38 25.55 10.01 15.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (290.51) (341.97) (337.71) (276.48) ‡‡‡‡‡ — —
EBT
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (21,036.13%) (1,338.66%) (3,374.72%) (1,800.58%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (290.51) (341.97) (337.71) (276.48) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.31 (5.49) (6.85) 0.91 — — —
Depreciation
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.21 0.07 0.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.59) (2.79) (2.36) (1.61) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.04) (2.45) (1.74) (1.37) ‡‡‡‡‡ — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.08) (0.03) (0.01) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.13) (2.48) (1.76) (1.37) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.47 6.13 5.44 3.30 ‡‡‡‡‡ — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.23 122.58 142.87 171.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — — — ‡‡‡ ‡‡‡‡‡ 1,222.30 56.91 16.66 57.24 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 1.78 1.93 0.76 2.56 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — ‡‡‡ ‡‡‡‡‡ 540.25 29.70 (3.90) 37.54 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
— — — — ‡‡‡‡‡ ‡‡‡‡‡ (3.13) (2.49) 0.55 (4.04) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (229.49) (300.32) (249.11) (235.45) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.06) (4.13) (2.02) (0.41) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (238.55) (304.44) (251.12) (235.86) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 955.80 739.83 758.48 552.70 — — —
Working Cap'
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 57.00 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (941.92) (750.09) (781.32) (554.52) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 950.22 752.00 777.79 567.06 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (27.56%) (35.19%) (39.38%) (37.05%) ‡‡‡‡‡ — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ (2,253.31%) (12,160.29%) 0.00% (1,508.62%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (31.44%) (40.18%) (44.15%) (41.12%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Relay Therapeutics (RLAY) trades at depressed levels after shedding most post-IPO gains, reflecting deep skepticism amid relentless cash burn and pipeline risks in precision oncology. Analyst price targets point to 35-110% upside from recent closes, betting on the innovative Dynamo platform’s protein motion modeling, but this hinges on navigating binary clinical outcomes in a sector where 90% of Phase 2 trials fail. With no insider buys in over a year and steady C-suite selling—over 2.8 million shares dumped via 10b5-1 plans—the narrative screams caution despite flashes of scientific promise and a still-cash-rich balance sheet.

Financials expose a burning cash engine: free cash flow per share deteriorated 114% over three years to -$1.76 in 2024, torching $251 million last year while runway shrinks to perhaps 2-3 years without dilution. Revenue remains lumpy and tiny—$10 million in 2024—versus ballooning R&D losses, with ROE at -44% and revenue per employee plunging 93% to $38,300 amid headcount cuts. Book value holds at a cheap 0.76x PB ratio, but eroding net cash and worsening EBT margins signal operational strain.

Pipeline leads like RLY-4008 and RLY-2608 offer de-risking potential via 2025-2027 data and partnerships, with projected revenue doubling by 2027, yet continued deep losses and high EV/Sales multiples underscore the high-stakes gamble. For risk-averse portfolios, Relay’s undervalued assets clash with execution pitfalls—read the full analysis for correlations, projections, and whether dilution or catalysts tip the scales.

Read full commentary →

Relay Therapeutics, Inc. (RLAY) Latest News

News by impact score

Fine-tune

3 Sep

4 , 10:32 AM
RXRX pipeline expansion adds new development programs targeting additional disease areas, positioning the company for extended growth through diversified drug candidates and extended R&D runway. Pipeline expansion marks a major strategic move expected to meaningfully shift competitive positioning and long-term trajectory.

20 Aug

4 , 8:01 AM
Relay Therapeutics advances its AI-powered drug discovery platform to accelerate development of precision medicines, positioning the company for potential growth and competitive gains in the biotech sector. AI-driven platform advances signal major strategic progress likely to reshape Relay's drug pipeline and investor outlook.

19 Aug

3 , 8:16 PM
Relay Therapeutics reported Q2 results, with analysis questioning whether its premium price-to-book multiple is justified by current performance and outlook. Q2 earnings disclosure and valuation assessment can shift near-term investor sentiment on financial trajectory without altering long-term fundamentals.

13 Aug

3 www.barchart.com, 11:00 AM
Relay Therapeutics (RLAY) stock has risen nearly 500% over the past year. Strong past stock gains reflect positive momentum that may support near-term investor interest without guaranteeing fundamental shifts.

6 Aug

3 , 4:05 PM
Relay Therapeutics reported second quarter 2026 financial results and corporate updates. Quarterly financial results and updates typically produce moderate effects on near-term stock movement and sentiment.

11 Jun

3 Insider Monkey, 6:20 AM
Relay Therapeutics (RLAY) ranks among top AI-driven biotech stocks based on its platform and pipeline. Positive labeling as leading AI biotech stock can lift short-term investor sentiment toward RLAY.

22 May

4 www.fool.com, 5:50 PM
Relay Therapeutics reports promising clinical trial results raising investor questions on whether the stock is a buy. Promising trial results signal major potential advances in drug pipeline and investor sentiment for Relay Therapeutics.

21 May

3 Simply Wall St., 10:16 PM
Relay Therapeutics (RLAY) shares rose 6.9% after a follow-on offering and early Zovegalisib data release. Follow-on offering supplies development capital while early Zovegalisib data offers pipeline progress for Relay Therapeutics.

20 May

3 GlobeNewswire, 8:21 PM
Relay Therapeutics priced its public offering of common stock to raise capital through issuance of new shares. Public stock offering supplies fresh capital for R&D while diluting existing shares and pressuring near-term valuation.

3 www.fool.com, 7:21 PM
Relay Therapeutics shares rose sharply Wednesday after the company reported encouraging early-stage trial data for its lead precision oncology candidate, lifting investor sentiment around its pipeline progress. Positive clinical update can lift near-term sentiment and valuation but remains early-stage without immediate revenue impact.

19 May

4 investorshub.advfn.com, 9:31 AM
Relay Therapeutics shares surged after positive results from its vascular anomalies clinical trial. Positive trial data strengthens Relay Therapeutics pipeline prospects and investor sentiment.

4 Investor's Business Daily, 6:00 AM
Relay Therapeutics' drug significantly beat forecasts, driving positive momentum for the company's pipeline and market standing. Drug results exceeding forecasts signal major upside for RLAY revenue potential and investor sentiment.

4 GlobeNewswire, 6:00 AM
Relay Therapeutics reported initial clinical data showing Zovegalisib has potential for differentiated safety and efficacy in PIK3CA-driven vascular anomalies patients. Positive early clinical results for Zovegalisib strengthen Relay Therapeutics pipeline value and investor outlook.

4 www.biopharmadive.com, 4:05 AM
Relay Therapeutics drug demonstrates early positive results against rare blood vessel diseases. Early clinical promise directly strengthens pipeline value and investor outlook for Relay Therapeutics.

3 GlobeNewswire, 4:03 PM
Relay Therapeutics, Inc. announces a proposed public offering of common stock to raise capital. Public stock offering adds capital for operations but dilutes shares and pressures near-term valuation.

8 May

3 Simply Wall St., 10:11 AM
Analysts have cut earnings estimates and price targets for Relay Therapeutics (RLAY), with average price target dropping to $18.50 from $25.40, citing pipeline delays and RLY-2608 trial concerns, leading to a Consensus Rating of Hold. Analyst estimate cuts pressure near-term stock price and investor sentiment without fundamentally altering long-term pipeline prospects.

5 May

4 GlobeNewswire, 4:05 PM
Relay Therapeutics reported first quarter 2026 financial results and provided corporate updates. Quarterly financial results and corporate updates signal major pipeline progress and financial health, significantly impacting investor sentiment and stock trajectory.

2 May

4 Simply Wall St., 12:28 AM
Relay Therapeutics advances zovegalisib to Phase 3 clinical trials while its valuation gap persists. Advancing zovegalisib to Phase 3 marks a major clinical milestone that could significantly enhance RLAY's pipeline value and market trajectory.

28 Apr

4 www.marketbeat.com, 1:04 AM
Relay Therapeutics unveiled positive zovegalisib triplet combination data and signed a supply agreement with Pfizer to support its Phase III development program. Advancing zovegalisib to Phase III with positive triplet data and Pfizer partnership represents a major strategic milestone for RLAY's pipeline.

27 Apr

4 GlobeNewswire, 6:00 AM
Relay Therapeutics announced clinical data for zovegalisib plus atirmociclib triplet combination supportive of further development in frontline metastatic breast cancer. Positive clinical data advancing a triplet combination into frontline metastatic breast cancer significantly bolsters Relay Therapeutics' oncology pipeline and investor sentiment.

4 Apr

4 Simply Wall St., 12:13 PM
Relay Therapeutics (RLAY) shares surged 30.6% after expanding zovegalisib into vascular anomalies with revealing data. Zovegalisib expansion into vascular anomalies backed by data triggered 30.6% stock rise, marking major pipeline progress.

3 Apr

4 Insider Monkey, 2:41 AM
Relay Therapeutics (RLAY) shares surged 16% in anticipation of an upcoming update on its cancer treatment. 16% stock climb ahead of cancer treatment update signals major potential advancement in core oncology pipeline.

2 Apr

3 GlobeNewswire, 4:05 PM
Relay Therapeutics to present initial clinical data on zovegalisib in vascular anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026. Initial clinical data presentation signals moderate pipeline progress in a new indication but remains early-stage with limited near-term market impact.

16 Mar

4 GlobeNewswire, 7:00 AM
Relay Therapeutics announces data from zovegalisib + fulvestrant at the Phase 3 dose of 400mg BID fed, presented at ESMO Targeted Anticancer Therapies Congress 2026. Phase 3 dose data presentation for zovegalisib combo at major oncology congress signals major pipeline progress with potential to alter competitive positioning and investor sentiment.

28 Feb

4 Simply Wall St., 9:07 AM
Relay Therapeutics (RLAY) secures Breakthrough Therapy designation, reports narrower quarterly loss, sparking valuation rally and renewed investor interest. Breakthrough Therapy designation accelerates RLAY's lead drug approval path while narrower losses improve financial outlook, significantly enhancing competitive position and investor sentiment.

27 Feb

4 www.fool.com, 11:18 AM
Relay Therapeutics (RLAY) stock surged 235% over the past year, fueled by a major fund increasing its stake to $110 million. Massive 235% stock gain and fund's $110 million bet increase demonstrate strong investor confidence likely to enhance market performance and trajectory.

26 Feb

4 GlobeNewswire, 4:05 PM
Relay Therapeutics reported fourth quarter and full-year 2025 financial results and outlined anticipated 2026 milestones. Financial results and pipeline milestones represent major updates that significantly shape investor sentiment and company trajectory.

7 Feb

4 Simply Wall St., 4:04 PM
Relay Therapeutics, Inc. received FDA Breakthrough Therapy Designation for its drug Zovegalisib, aimed at treating specific cancers. This designation is expected to expedite the development and review process, potentially enhancing the drug's market prospects and Relay's overall valuation. Analysts are assessing the implications of this designation on the company's future performance and market position. The FDA Breakthrough Therapy Designation is likely to significantly enhance Zovegalisib's development timeline and market potential, impacting Relay's trajectory.

4 Feb

3 GlobeNewswire, 4:05 PM
Relay Therapeutics, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its ongoing engagement in the biotech sector and potential strategic discussions with investors and industry leaders. Participation in industry summits can enhance visibility and networking opportunities, potentially influencing future collaborations and market sentiment.

3 Feb

4 GlobeNewswire, 7:00 AM
Relay Therapeutics, Inc. announced that the U.S. FDA has granted Breakthrough Therapy Designation for Zovegalisib, a treatment for patients with PIK3CA-mutant, HR+/HER2- advanced breast cancer. This designation aims to expedite the development and review process for the drug, highlighting its potential to address unmet medical needs in this patient population. The Breakthrough Therapy Designation is a significant regulatory milestone that could enhance Zovegalisib's market position and accelerate its path to commercialization.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us